Proteomics International Laboratories has revealed new results showing that refinement of its...
Proteomics International (ASX:PIQ) to present new oesophageal cancer test at global conference – The Market Herald
“We’ve refined our diagnostic models to correctly identify 89 per cent of patients with oesophageal adenocarcinoma and 92 per cent of patients without the disease,” PIQ Managing Director Dr Richard Lipscombe said.
Article: Proteomics International (ASX:PIQ) to present new oesophageal cancer test at global conference